Since cancer stem cells (CSCs) and quiescent tumor cells share signaling pathways, as in the case of mitogen-activated protein kinase P38 (P38 MAPK), the development of therapeutic approaches targeting p38 may increase tumor sensitivity to chemotherapy and prevent progression and metastasis. This evidence concerns the gene MAPK14 and cancer.